[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Alnylam Pharmaceuticals, Inc. (ALNY)
Alnylam Pharmaceuticals repurchases $XXXX million in convertible notes, while also facing scrutiny over Amvuttra pricing and FDA ad regulations.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference (RNAi) therapeutics.
Alnylam Pharmaceuticals, Inc. uses the ticker $ALNY for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- Alnylam Pharmaceuticals, Inc. (ALNY) market dominance near a 52-week low at XXXXXXX.
- Alnylam Pharmaceuticals, Inc. (ALNY) trading volume is up XXXX% from the previous week.
- Alnylam Pharmaceuticals, Inc. (ALNY) social dominance is up XXXXXX% from the previous X months.
- Alnylam Pharmaceuticals, Inc. (ALNY) engagements is up XXXXXX% from the previous week.
Price: $XXXXXX
Price 24-Hour Time-Series Raw Data
The stock price is experiencing volatility due to mixed news, with positive clinical trial data and strong sales being offset by regulatory concerns and negative social media sentiment, leading to a balanced outlook.
24-Hour: XXXX% 7-Day: -XXXXX% 30-Day: -XXXX%
1-Year High: $XXXXXX on 2025-10-20
1-Year Low: $XXXXXX on 2025-04-08
AltRank: XXX
AltRank 24-Hour Time-Series Raw Data
Alnylam Pharmaceuticals, Inc. (ALNY) is currently AltRank #259 based on combined combined social and market metrics
Daily Average: XXX
X Week: XXX -XXX
X Month: XXX -XXX
X Months: XXX +107
X Year: XXX -XXX
1-Year High: XXXXX on 2025-06-26
1-Year Low: X on 2025-03-22
Galaxy Score: XXXXX
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
X Week: XX -X
X Month: XX -X
X Months: XX -X
X Year: XX -X
1-Year High: XX on 2025-02-19
1-Year Low: XX on 2025-06-26
Engagements: XXXXX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXXXXX
X Week: XXXXXX +163%
X Month: XXXXXXX -XX%
X Months: XXXXXXXXX +13%
X Year: XXXXXXXXX -XX%
1-Year High: XXXXXXX on 2025-03-21
1-Year Low: XXX on 2025-12-07
Engagements by network (24h): Reddit: X X: XXXXX
Mentions: XXX (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XXX
X Week: XXX -XX%
X Month: XXX -XX%
X Months: XXXXX +21%
X Year: XXXXX -XX%
1-Year High: XXX on 2025-08-13
1-Year Low: XX on 2025-12-07
Mentions by network (24h): Reddit: X X: XXX
Creators: XX (24h)
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning Alnylam Pharmaceuticals, Inc. (ALNY) in the last XX hours which is down XXXX% from XX in the previous XX hours
Daily Average: XXX
X Week: XXX -XXXX%
X Month: XXX -XXXX%
X Months: XXXXX +105%
X Year: XXXXX +58%
1-Year High: XXX on 2025-06-28
1-Year Low: XX on 2025-12-07
The most influential creators that mention Alnylam Pharmaceuticals, Inc. in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @Andre_AGTC | X | XXXXX | X | XXX |
| @USCorpFilings | X | XXXXX | X | XXX |
| @BiopharmIQ | X | XXXXXX | X | XXX |
| @DwightS2025 | X | XXX | X | XX |
| @RNAiAnalyst | X | XXXXXX | X | XX |
| @john_steel70462 | X | XXX | X | XX |
| @seedytx19 | X | XXXXX | X | XX |
| @RosaJim94865433 | X | XXX | X | XX |
| @ElsaPhe22932079 | X | XXX | X | XX |
| @Biobeats99 | XX | XXX | X | XX |
Sentiment: XX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XX% no change
X Month: XX% -X%
X Months: XX% +9%
X Year: XX% -XX%
1-Year High: XXX% on 2025-07-29
1-Year Low: XX% on 2025-12-02
Most Supportive Themes:
- Positive Data from HELIOS-B Study: (35%) New data from the HELIOS-B Phase X study shows reduced gastrointestinal events in ATTR-CM patients treated with Vutrisiran, supporting its use as a first-line therapy.
- Amvuttra Sales and Revenue Guidance: (20%) Alnylam reported strong Amvuttra sales and increased its 2025 revenue guidance, indicating positive financial performance.
- First Patient Dosed in ZENITH Trial: (15%) Alnylam announced the first patient has been dosed in the ZENITH Global Phase X cardiovascular outcomes trial of Zilebesiran, marking progress in its clinical pipeline.
Most Critical Themes:
- Negative Sentiment on X: (20%) A significant portion of posts on X express negative sentiment, with users raising concerns about the company.
- FDA Crackdown and Ad Pull: (10%) Alnylam has withdrawn TV advertisements following regulatory action on drug industry advertising, which may lead to concerns.
Social Dominance: XXXX%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXX%
Daily Average: XXXX%
X Week: XXXXXX% +0.0028%
X Month: XXXXX% +0.026%
X Months: XXXXX% +0.029%
X Year: XXXXX% -XXXXXX%
1-Year High: XXXXX% on 2025-01-23
1-Year Low: XXXXXX% on 2025-12-07
Market Dominance: XXXXX%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXX%
Daily Average: X%
1-Year High: XXXX% on 2025-12-02
1-Year Low: XXXXX% on 2025-12-11
Market Cap: $XXXXXXXXXXXXXX
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXXX -$11%
X Month: $XXXXXXXXXXXXXX -$8.70%
X Months: $XXXXXXXXXXXXXX +$36%
X Year: $XXXXXXXXXXXXXX +$66%
1-Year High: $XXXXXXXXXXXXXX on 2025-10-20
1-Year Low: $XXXXXXXXXXXXXX on 2025-04-08
Top Alnylam Pharmaceuticals, Inc. Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$ALNY Notes Repurchase: On December XX 2025 Alnylam Pharmaceuticals repurchased about $XXXX million of its convertible senior notes for approximately $XXXX million in total cost. Following this approximately $XXXXX million of the notes will remain outstanding"
X Link @USCorpFilings 2025-12-11T12:45Z 6831 followers, XXX engagements
"$ALNY - Alnylam Pharmaceuticals plans to repurchase about $XXXX million of its convertible senior notes for approximately $XXXX million with adjustments based on stock price. Read more on"
X Link @visufinance 2025-12-11T12:28Z XXX followers, XX engagements
"🔴🔥 $ALNY Alnylam Pharmaceuticals Inc. repurchases $XXXX million in convertible notes for $XXXX million On December XX 2025 Alnylam Pharmaceuticals Inc. #SEC #8K #Pharma #Biotech"
X Link @booooogy01 2025-12-11T12:26Z X followers, XX engagements
"Bernstein🏁 $BBIO at an Outperform-$94 and said 'Ample Upside Even if Attruby Hits Choppy Seas. Initiate at Outperform $XX PT' $ALNY $PFE AZN BAYRY BMRN ASND Bernstein additionally said in its BridgeBio initiation report: We believe expectations for ATTR-CM drug Attruby are reasonable near/mid-term and arguably too high long term while we see upside to consensus numbers for infigratinib and encaleret. We are in line for BBP-418. Key proprietary analyses in this initiation: ATTR-CM doc survey infigratinib doc feedback infigratinib Ph3 trial analysis. Our survey of N=30 ATTR docs was less"
X Link @Quantumup1 2025-12-11T11:13Z 3927 followers, 1551 engagements